Since, the expressions of the gene signatures do not necessarily correlate with the actual number of cells, in our fifth approach, we directly evaluated the percentage of CD4+CD25+FOXP3+ Tregs from breast tumor patient-derived blood samples. This evidence concerns the gene FOXP3 and breast neoplasm.